sgn-15
mAbexperimentalADC
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2000 (NCT00028483)
Timeline
2000s
- Jan 1, 2000
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Lewis Y antigenBINDING AGENT
Lewis Y antigen binding agent
- Lewis Y antigenImmunity, passive
Lewis Y antigen immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- doxorubicin
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109502 ↗
- ChEMBLCHEMBL2109285 ↗
Also known as
- bms 182248
- bms-182248
- bms-182248
- br96
- br-96 cbr96-doxorubicin immunoconjugate
- br96-doxorubicin immunoconjugate
- cbr96-doxorubicin immunoconjugate
- sgn-15
- sgn-15
- sgn-15
- sng-15
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00086333 | Phase 2 | Jul 1, 2004 | Seattle Genetics |
| NCT00051571 | Phase 2 | Jan 13, 2003 | Seattle Genetics |
| NCT00051584 | Phase 2 | Jan 13, 2003 | Seattle Genetics |
| NCT00028483 | Phase 2 | Oct 1, 2000 | Seattle Genetics, University of Alabama, Birmingham |
| NCT00031187 | Phase 2 | Oct 1, 2000 | Seattle Genetics |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Seattle Genetics | For profit | 5 | 5 | 1 | 2000 |
| University of Alabama, Birmingham | Academic/Hospital | 1 | 0 | 1 | 2000 |
2 organizations
Page 1 / 1